WHO SHOULD ATTEND?
Clinicians involved in daily care for infectious disease patients; young medical professionals; scientists involved in antiviral drug resistance; researchers and PhD students active in this field.

WHY SHOULD YOU ATTEND?
• It is the premier Treatment Strategies & Antiviral Drug Resistance meeting for infectious disease doctors and clinical virologists.
• It offers a unique platform to discuss the latest developments in antiviral therapy for HIV, HCV and HBV and for translating them into new treatment strategies to further improve clinical care.
• This meeting is a stepping stone for young medical professionals to present their research in an informal and encouraging setting. We stimulate their participation by offering them a complimentary registration (for more information see meeting website).
• The meeting will be CME accredited, guaranteeing exceptional quality and unbiased educational activities. The credits gained are recognised by most national CME authorities in Europe, USA and Canada.
• Host city Barcelona is one of the most charming cities in the world – a true cultural capital with vibrancy and flair. We have scheduled this meeting in June so that you can enjoy the city at its best!
ABSTRACT SUBMISSION

We invite you to submit your abstracts in the following categories:

• Mechanism of Antiviral Drug Resistance
• Resistance to Antiviral Drugs
• Spread of Drug Resistance
• Clinical Implications of Antiviral Drug Resistance
• Novel Diagnostic Technologies & Approaches
• Treatment Strategies for HIV/Hepatitis infected Patients
• Therapeutic Challenges in Resource-limited settings
• Viral Evolution & Genetic Diversity
• Clinical case

Abstract submission deadline: 27 March 2015

WHAT WILL BE DISCUSSED?

• Is resistance testing for drug naïve patients needed for clinical management?
• Do we need to know the “Source”? Is transmission chain analysis ethical?
• Are induction maintenance strategies a real clinical option, which data is needed?
• When can we expect interferon-free HCV regimens?
• Is resistance development to DAA in HCV a future clinical problem?
• European Cohorts: what did we achieve? What are the goals?
• Which are the next steps required to cure HBV?

For full overview, please visit the meeting website at www.virology-education.com. Information will be updated regularly.